Literature DB >> 23798711

LIN28B-mediated expression of fetal hemoglobin and production of fetal-like erythrocytes from adult human erythroblasts ex vivo.

Y Terry Lee1, Jaira F de Vasconcellos, Joan Yuan, Colleen Byrnes, Seung-Jae Noh, Emily R Meier, Ki Soon Kim, Antoinette Rabel, Megha Kaushal, Stefan A Muljo, Jeffery L Miller.   

Abstract

Reactivation of fetal hemoglobin (HbF) holds therapeutic potential for sickle cell disease and β-thalassemias. In human erythroid cells and hematopoietic organs, LIN28B and its targeted let-7 microRNA family, demonstrate regulated expression during the fetal-to-adult developmental transition. To explore the effects of LIN28B in human erythroid cell development, lentiviral transduction was used to knockdown LIN28B expression in erythroblasts cultured from human umbilical cord CD34+ cells. The subsequent reduction in LIN28B expression caused increased expression of let-7 and significantly reduced HbF expression. Conversely, LIN28B overexpression in cultured adult erythroblasts reduced the expression of let-7 and significantly increased HbF expression. Cellular maturation was maintained including enucleation. LIN28B expression in adult erythroblasts increased the expression of γ-globin, and the HbF content of the cells rose to levels >30% of their hemoglobin. Expression of carbonic anhydrase I, glucosaminyl (N-acetyl) transferase 2, and miR-96 (three additional genes marking the transition from fetal-to-adult erythropoiesis) were reduced by LIN28B expression. The transcription factor BCL11A, a well-characterized repressor of γ-globin expression, was significantly down-regulated. Independent of LIN28B, experimental suppression of let-7 also reduced BCL11A expression and significantly increased HbF expression. LIN28B expression regulates HbF levels and causes adult human erythroblasts to differentiate with a more fetal-like phenotype.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23798711      PMCID: PMC3739030          DOI: 10.1182/blood-2012-12-472308

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

Review 1.  Pathophysiology of thalassaemia.

Authors:  D J Weatherall
Journal:  Baillieres Clin Haematol       Date:  1998-03

2.  Hemoglobin switching.

Authors:  A W Nienhuis; G Stamatoyannopoulos
Journal:  Cell       Date:  1978-09       Impact factor: 41.582

Review 3.  The intracellular polymerization of sickle hemoglobin and its relevance to sickle cell disease.

Authors:  C T Noguchi; A N Schechter
Journal:  Blood       Date:  1981-12       Impact factor: 22.113

4.  Conservation of the heterochronic regulator Lin-28, its developmental expression and microRNA complementary sites.

Authors:  Eric G Moss; Lingjuan Tang
Journal:  Dev Biol       Date:  2003-06-15       Impact factor: 3.582

5.  The transcriptome profile of human embryonic stem cells as defined by SAGE.

Authors:  Mark Richards; Siew-Peng Tan; Jee-Hian Tan; Woon-Khiong Chan; Ariff Bongso
Journal:  Stem Cells       Date:  2004       Impact factor: 6.277

6.  Identification of mRNAs bound and regulated by human LIN28 proteins and molecular requirements for RNA recognition.

Authors:  Markus Hafner; Klaas E A Max; Pradeep Bandaru; Pavel Morozov; Stefanie Gerstberger; Miguel Brown; Henrik Molina; Thomas Tuschl
Journal:  RNA       Date:  2013-03-12       Impact factor: 4.942

7.  5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia.

Authors:  T J Ley; J DeSimone; N P Anagnou; G H Keller; R K Humphries; P H Turner; N S Young; P Keller; A W Nienhuis
Journal:  N Engl J Med       Date:  1982-12-09       Impact factor: 91.245

8.  Biosynthesis of blood group I antigens. Identification of a UDP-GlcNAc:GlcNAc beta 1-3Gal(-R) beta 1-6(GlcNAc to Gal) N-acetylglucosaminyltransferase in hog gastric mucosa.

Authors:  F Piller; J P Cartron; A Maranduba; A Veyrières; Y Leroy; B Fournet
Journal:  J Biol Chem       Date:  1984-11-10       Impact factor: 5.157

9.  Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes.

Authors:  G M Brittenham; A N Schechter; C T Noguchi
Journal:  Blood       Date:  1985-01       Impact factor: 22.113

10.  Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.

Authors:  O S Platt; S H Orkin; G Dover; G P Beardsley; B Miller; D G Nathan
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

View more
  59 in total

1.  microRNA-dependent temporal gene expression in the ureteric bud epithelium during mammalian kidney development.

Authors:  Vidya K Nagalakshmi; Volkhard Lindner; Andy Wessels; Jing Yu
Journal:  Dev Dyn       Date:  2014-11-23       Impact factor: 3.780

2.  Transcriptional environment and chromatin architecture interplay dictates globin expression patterns of heterospecific hybrids derived from undifferentiated human embryonic stem cells or from their erythroid progeny.

Authors:  Kai-Hsin Chang; Andy Huang; Hemei Han; Yi Jiang; Xiangdong Fang; Chao-Zhong Song; Steve Padilla; Hao Wang; Hongzhu Qu; John Stamatoyannopoulos; Qiliang Li; Thalia Papayannopoulou
Journal:  Exp Hematol       Date:  2013-08-28       Impact factor: 3.084

3.  Lin28b regulates age-dependent differences in murine platelet function.

Authors:  Massiel Chavez Stolla; Seana C Catherman; Paul D Kingsley; R Grant Rowe; Anne D Koniski; Katherine Fegan; Leah Vit; Kathleen E McGrath; George Q Daley; James Palis
Journal:  Blood Adv       Date:  2019-01-08

Review 4.  Fetal hemoglobin in sickle cell anemia: The Arab-Indian haplotype and new therapeutic agents.

Authors:  Alawi H Habara; Elmutaz M Shaikho; Martin H Steinberg
Journal:  Am J Hematol       Date:  2017-08-17       Impact factor: 10.047

5.  Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR/γ-globin looping.

Authors:  Ivan Krivega; Colleen Byrnes; Jaira F de Vasconcellos; Y Terry Lee; Megha Kaushal; Ann Dean; Jeffery L Miller
Journal:  Blood       Date:  2015-05-15       Impact factor: 22.113

Review 6.  Erythrocyte microRNAs: a tiny magic bullet with great potential for sickle cell disease therapy.

Authors:  Henu Kumar Verma; Yashwant Kumar Ratre; L V K S Bhaskar; Raffaella Colombatti
Journal:  Ann Hematol       Date:  2021-01-04       Impact factor: 3.673

Review 7.  Omics Studies in Hemoglobinopathies.

Authors:  Eleni Katsantoni
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

Review 8.  Fetal haemoglobin induction in sickle cell disease.

Authors:  Alireza Paikari; Vivien A Sheehan
Journal:  Br J Haematol       Date:  2017-11-16       Impact factor: 6.998

Review 9.  Customizing the genome as therapy for the β-hemoglobinopathies.

Authors:  Matthew C Canver; Stuart H Orkin
Journal:  Blood       Date:  2016-04-06       Impact factor: 22.113

Review 10.  Minireview: Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine.

Authors:  Steven R Goodman; Betty S Pace; Kirk C Hansen; Angelo D'alessandro; Yang Xia; Ovidiu Daescu; Stephen J Glatt
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.